Antagonists of melanin concentrating hormone receptor

US6921821B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Christopher Blackburn · Las Vegas, US
• Su-Jen Lai · Somerville, US
• Jennifer L. Che · Cambridge, US
• Martin P. Maguire · Westmount, CA
• Michael A. Patane · Harleysville, US
• Matthew J. LaMarche · Reading, US
• Courtney A. Cullis · Bedford, US
• James Brown · Moorpark, US
• Anil Vasudevan · Union Grove, US
• Jennifer Freeman · Grayslake, US
• Mathew M. Mulhern · Hainesville, US
• John Lynch · Kenosha, US
• Ju Gao · Gurnee, US
• Dariusz Wodka · Waukegan, US
• Andrew J. Souers · Libertyville, US
• Rajesh Iyengar · Newton, US
• Mary Verzal · Burlington, US
• Philip R. Kym · Libertyville, US

Key dates

• Filing date: Jun 11, 2003
• Grant date: Jul 26, 2005
• Expiry date: Jun 11, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: where m is zero or one, n is zero to two, Y is oxygen or —N(R9)—, R1, R2, R3, R4, R5, R9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.